知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

362 条记录 (耗时 0.038 秒)

    SCREENING FOR THE EFFECTS OF COMPLEMENT PROTEIN CHANGES
    1.
    发明公开
    SCREENING FOR THE EFFECTS OF COMPLEMENT PROTEIN CHANGES 审中-公开

    公开(公告)号：US20240255503A1

    公开(公告)日：2024-08-01

    申请号：US18565377

    申请日：2022-05-25

    申请人： UNIVERSITY OF NEWCASTLE UPON TYNE

    发明人： Thomas HALLAM ,  Kevin MARCHBANK ,  David KAVANAGH ,  Claire HARRIS

    IPC分类号： G01N33/564 ,  C07K14/47 ,  G01N33/543

    CPC分类号： G01N33/564 ,  C07K14/472 ,  G01N33/54373 ,  G01N2333/4716

    摘要： Aspects of the present invention relate to the detection of binding events associated with a protein complex comprised of a protease deficient Complement Factor I (FI) protein. Certain embodiments of the present invention provide for a protein complex comprising a Complement Factor I, C3b and further comprising at least one other protein from Complement Factor H (FH), Factor-H-like protein 1 (FHL-1), soluble membrane cofactor protein (sMCP), and soluble complement receptor 1 (sCR1), wherein the Complement Factor I comprises at least one mutation that causes inactivation of Complement Factor I protease activity. Further embodiments of the present invention provide for a protein complex comprising a Complement Factor I, C4b and further comprising at least one other protein from soluble complement receptor 1 (sCR1), soluble membrane cofactor protein (sMCP) and C4b binding protein (C4bp), wherein the Complement Factor I comprises at least one mutation that causes inactivation of Complement Factor I protease activity.

    INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES
    4.
    发明公开
    INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES 审中-公开

    公开(公告)号：US20230287051A1

    公开(公告)日：2023-09-14

    申请号：US18016490

    申请日：2021-07-15

    申请人： ZP SPV 3 K/S

    发明人： Anne Pernille Tofteng SHELTON ,  Henrik Fischer MUNCH ,  Rasmus LETH

    IPC分类号： C07K7/08 ,  A61P37/06 ,  C07K14/47

    CPC分类号： C07K7/08 ,  A61P37/06 ,  C07K14/472

    摘要： Compstatin analogues having improved physicochemical properties, such as increased stability and/or solubility as compared to the 13 amino acid compstatin peptide are described, in particular compstatin analogues that additionally possess useful binding and complement-inhibiting activity. These analogues have an alkylene bridge between sulphur atoms of cysteine residues and include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing stability, such as the introduction of lysine or serine at position 11.

    COMPLEMENT INHIBITORS AND USES THEREOF
    7.
    发明申请
    COMPLEMENT INHIBITORS AND USES THEREOF 审中-公开

    公开(公告)号：US20190202878A1

    公开(公告)日：2019-07-04

    申请号：US16311711

    申请日：2017-06-28

    申请人： UNIVERSITAT ULM

    发明人： Christoph SCHMIDT ,  Hubert SCHREZENMEIER ,  Markus ANLIKER ,  Britta HOECHSMANN

    IPC分类号： C07K14/47

    CPC分类号： C07K14/472 ,  A61K38/00

    摘要： The present invention relates to a multi-domain polypeptide comprising (i) a first complement control protein repeat (CCP)-comprising domain being a convertase decay accelerating domain for convertases of the classical and alternative pathways of complement activation, (ii) a host cell recognition domain, and (iii) a second CCP-comprising domains with cofactor activity. The present invention further relates to a polynucleotide encoding said multi-domain polypeptide, to a vector comprising said polynucleotide, and to a host cell comprising said polynucleotide and/or said vector. Further, the present invention relates to the multi-domain polypeptide, the polypeptide, and the vector for use in medicine and for treating and/or preventing inappropriate complement activation and/or a disease having inappropriate complement activation as a symptom. Moreover, the present invention relates to methods and uses related to multi-domain polypeptide, the polypeptide, and the vector.

    Antibodies to the C3d fragment of complement component 3
    10.
    发明授权
    Antibodies to the C3d fragment of complement component 3 有权

    公开(公告)号：US09815890B2

    公开(公告)日：2017-11-14

    申请号：US13805522

    申请日：2011-06-22

    申请人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    发明人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

    CPC分类号： C07K16/18 ,  C07K14/472 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.